The Bigger Picture

Owned by Alex
Last updated: Mar 26, 2024
50 min read

Author

  • Christine Maggiore

Publisher

  • -

Category

  • Controversy

Topic

  • AIDS Paradox

  • AIDS Dilemma

  • W.H.O.

Article Type

  • Editorial Article

Publish Year

  • 1996

Meta Description

  • The content discusses the controversy around AIDS information, with some groups rejecting alternative perspectives. It also highlights the dependency on federal AIDS funding.

Summary

  • This text discusses the limitations on public awareness and questioning of information about HIV and AIDS. It highlights how AIDS organizations and mainstream media often discourage questioning of established AIDS science. The text also mentions the lack of investigative reporting on AIDS and the prevalence of uncritical reporting that reinforces official views. It further discusses how institutions and organizations may reject alternative perspectives on AIDS and label them as dangerous. The text emphasizes the need for open debate and exploration of new ideas, which is often lacking in the context of AIDS.

Meta Tag

  • AIDS

  • Information

  • Controversy

  • Rejection

  • Alternative Perspectives

  • Federal Funding

  • HIV

  • Testing

  • WHO Estimates

  • Medical Protocols

  • Consensus

  • Treatment Drugs

Featured Image

 

Featured Image Alt Tag

  • Keyword of the image

By Christine Maggiore
This is a chapter from the book
What if everything you thought about AIDS was wrong?
http://www.aliveandwell.org

Are These Facts News to You?

Why are we not getting all the facts about HIV and AIDS? Why do media reports uncritically promote HIV testing and the notion that everyone is at risk for AIDS? Why do the AIDS organizations supported by our tax dollars and donations leave the information addressed in this book out of their education programs and advertising campaigns? Some answers to these questions may be found by examining our current AIDS funding and research systems which offer little incentive for critical review, forthright discussion and innovation, but which are the source of most AIDS news.

Total tax dollars spent on AIDS presently exceeds $50 billion. Annual AIDS funding increases every year and is one of the only areas of the federal budget that has faced no threat of cuts. The high priority given to AIDS is based on the notion that AIDS poses a widespread and ever-growing health threat to all Americans. Since the government institutions responsible for generating official AIDS reports are the recipients of these multi-billions in AIDS dollars, it is understandable that the information they disseminate would support, rather than challenge the idea that AIDS is a large and growing problem. Their official reports are the basis for most AIDS newsreports that are not analyzed or investigated before they are repeated by the media and AIDS groups.

Investigative media reports on AIDS are generally discouraged because of sensitivity to the many social and political issues that surround HIV and AIDS. AIDS awareness, AIDS drugs, safe sex, and HIV testing are among the myriad concepts about AIDS that have been integrated into popular culture. Widespread acceptance of these concepts makes challenges to current views on HIV and AIDS appear highly controversial or even too dangerous to report. As orthodox AIDS expert and Nobel Laureate Dr. David Baltimore has declared, "There is no question HIV is the cause of AIDS. Anyone who gets up publicly and says the opposite is encouraging people to risk their lives."155

The Los Angeles Times recently acknowledged the factors that can influence AIDS news in "Protest Averted," an article that recounts the decision by a local TV station to alter a broadcast that mentioned decreases in AIDS: "After being pressured by the Los Angeles Gay and Lesbian Community Services Center, KCBS-TV Channel 2 has revised a station editorial on AIDS, deleting the line that stated 'A new report by the CDC indicates that AIDS is down in all categories and is not an epidemic.'"156

Many AIDS activist organizations charge that critical examination of HIV and AIDS is equivalent to promoting unsafe sex and may cause HIV positives to stop or refuse necessary pharmaceutical treatment. One such group, the San Francisco based drug advocacy organization Project Inform, brought their concerns regarding AIDS critics before the National Academy of Sciences. Project Inform's founder, Martin Delaney, is a nationally recognized AIDS activist and a member of the National Institute of Allergy and Infectious Diseases (NIAID) Council on AIDS. The group's National Board of Governors includes HIV codiscoverer Dr. Robert Gallo and award-winning AIDS researcher Dr. David Ho. In 1997, Delaney petitioned the Academy asking them to expel members who engage in public challenges to the HIV=AIDS paradigm.157

In his letter to the Academy, Delaney denounces scientists who make information that questions AIDS available to "young and poorly informed people struggling with HIV infection [whose] natural inclination toward denial gives them a seemingly legitimate way to ignore a positive HIV antibody test, to cast aside...safe sex, and to forgo the complex challenge of multi-drug combination therapy." He suggests that AIDS is an area of public health that should not be examined in public forums, reasoning that "just as the blanket of free speech doesn't sanction the person who yells 'fire' in a crowded theater, neither does academic freedom provide protection for irresponsible behavior by scientists," and draws a parallel to criminal behavior claiming that "it is difficult to distinguish [the] actions [of scientists who raise questions about AIDS] from those of a mass murderer."

Attached to Project Inform's appeal is a list of supporting endorsements. Among the individuals and organizations joining the campaign to curtail critical discussion of AIDS science are AIDS Project Los Angeles; the Center for AIDS Prevention Studies at the University of San Francisco AIDS Research Institute; FAIR (Foundation for AIDS and Immune Research); the Florida AIDS Action Council; the United Foundation for AIDS; the Multicultural AIDS Coalition Inc.; Being Alive; Test Positive Aware Network; Gregory Britt, CEO of AIDS Research Alliance; noted AIDS researcher Dr. Michael Gottlieb; Brenda Freiberg, Chair of Public Policy at AIDS Service Center in Pasadena, California; Mary Lucey, President of Women Alive; and Dr. Martin Markowitz of the renowned Aaron Diamond Research Center in New York.

Project Inform's stance against information that questions AIDS is not unusual. For example, LA Shanti Foundation, a Los Angeles support network for people diagnosed with life-threatening illness, recently took a position on what many regard as life-affirming information about AIDS: My request to be considered as a speaker for their Positive Living For Us seminar, "a weekend for those who have tested positive for HIV...in which experts provide information about treatments, nutrition, sexuality, peer support, public benefits, insurance, legal matters, and other relevant topics," was not only rejected, my letter of inquiry was forwarded to the FDA's California AIDS Fraud Task Force, and to the District Attorney's AIDS Fraud Unit by the PLUS program manager, Ric Parish.158 When asked by The Valley Advocate newspaper for comments on the growing movement to rethink AIDS, Nancy MacNeill, program coordinator for the Los Angeles AIDS group Women Alive exclaimed, "We hate them. They're spreading dangerous information."159 Greg Gonsalves, founder of the New York City AIDS drug advocacy organization Treatment Action Group declared that "SPIN magazine's AIDS column is a public health menace" for its inclusion of alternative perspectives on AIDS.160 Imposing limits on what AIDS information may be brought before the public limits public awareness of different ideas about HIV and AIDS.

AIDS organizations that object to public questioning of AIDS science may take their lead from mainstream media venues where news that challenges common perceptions about AIDS is rare. Journalists who cover AIDS seldom engage in investigative reporting and many have built successful careers by reiterating official AIDS views. Uncritical AIDS reports are the ones that have earned awards and have afforded many writers celebrity status. Laurie Garrett of Newsday, for example, has received two Pulitzer Prizes for her coverage of AIDS and frequently appears on television alongside prominent AIDS researchers and government health officials. In a recent issue of Esquire magazine, Garrett described the PCR test, a test not indicated or approved for the detection of HIV and unable to measure actual virus, as measuring HIV with "exquisite specificity."161 Rather than rock the boat propelled by establishment AIDS views, high-level AIDS reporters generally dismiss or ignore challenges to the HIV=AIDS hypothesis.

Since the publications designed to reach HIV positives are funded almost entirely by AIDS drug manufacturers, it is not surprising that critical reporting on AIDS is absent from these venues. To cite just one example, AIDS pharmaceutical promotions filled 17 out of 31 pages allocated for advertisements in a current issue of A&U: America's AIDS Magazine. Of the remaining 14 pages, nine were purchased by viatical settlement groups offering cash in exchange for the life insurance policies of HIV positives.162

The research labs that produce the studies and reports that are turned into AIDS news all rely on some form of federal AIDS funding. Since the late 1980s, government support for AIDS research has been predicated on adherence to the HIV hypothesis. Institutions that depend on government dollars for support must assume that HIV is the cause of AIDS, and grants are not available to scientists or clinicians whose work may challenge the HIV hypothesis. For example, no funding has been provided for studies that compare the health of medicated and unmedicated HIV positives in matched control groups, for conducting viral load tests and T cell counts on HIV negatives matched to AIDS risk groups, or for verifying the accuracy of HIV antibody tests through isolation of actual virus in people with positive test results.

One well-known casualty of the AIDS funding system is Dr. Peter Duesberg of the University of California at Berkeley. Federal support for his laboratory was not renewed after his 1987 article in Cancer Research that questioned Gallo's HIV hypothesis and proposed an alternative AIDS hypothesis.163 Before 1987, Duesberg received ongoing funding as a recipient of the NIH's prestigious Outstanding Investigator Award. He was also a Nobel candidate for his discovery of oncogenes, and is a member of the National Academy of Sciences. Since raising challenges to the HIV hypothesis, Duesberg has had 21 consecutive research grant applications rejected by the NIH and other federal and state funding sources.164

Pharmaceutical company grants are another important source of AIDS research money that make objective circumstances for drug studies almost impossible to achieve. Surprisingly, it is not considered a conflict of interest when AIDS researchers own stock in the companies whose products they test, or when they are hired to run the drug trials they publish in medical journals. In fact, it is common practice for drug companies to pay researchers to author favorable articles about their products.165

Many AIDS scientists previously employed by the US government have gone into private AIDS enterprise, a practice that further blurs the lines between news, public relations, and private interests. For example, the former director of the US Centers for Disease Control, Dr. Donald Francis, used his reputation in government AIDS work and his access to the media to raise $40 million in private investment capital for his AIDS vaccine company VaxGen.166 In a recent CNN report on VaxGen, Francis promoted an AIDS vaccine as "the only way to stop a virus that is essentially 100 percent fatal."167 In fact, most media stories that incite fear of AIDS and praise AIDS drugs derive from press releases or studies generated by AIDS drug developers. Since the pharmaceutical industry, like any other profit-oriented business, seeks to increase sales and profitability, expand its consumer base, and maintain a favorable public image, it is understandable that their press releases would promote continued success rather than provide critical or unfavorable information. However, their press releases are rarely questioned or scrutinized before being reported as news.

While America's institutions of higher learning are considered appropriate arenas for exploration of new ideas, open debate and discussion, this is often not the case when it comes to AIDS. To take just one recent example, members of the Graduate Students Council at Einstein College of Medicine in New York were discouraged from having their invited guest, Dr. Peter Duesberg, speak on campus. After being voted the student-selected speaker over orthodox AIDS researcher Dr. David Baltimore, and NIH Director Dr. Harold Varmus, Duesberg was informed that faculty members had pressured students into canceling the event. As student council chairman Robert Glover explained, "The general consensus is that many people would be offended by Duesberg's visit."168

As AIDS advocacy and service providers have grown from grassroots groups into multimillion dollar corporations, it has become harder for leaders to consider new ideas and approaches to resolving AIDS. For example, the success formula for the $45 million nonprofit AIDS Health Care Foundation of Los Angeles is providing AIDS drugs to people who test HIV positive.169 Also, much of the money spent by AIDS groups comes from grants by pharmaceutical companies. To take just one example, the Washington, DC based National Association of People with AIDS receives funding from Merck, Glaxo-Wellcome, Roche, and Bristol-Myers Squibb.170 Such situations provide little incentive for challenging popular ideas about HIV and AIDS.

There are an estimated 90,000 AIDS organizations in the US, about one for every six Americans ever given a diagnosis of AIDS.171 Few, if any, of these groups evaluate the news they pass on to us in their education and awareness campaigns. Most repeat unexamined press releases from government agencies, the pharmaceutical industry and government-funded labs to the exclusion of all other information. And most will not participate in public discussion of the questions raised in this book.

Over 100 AIDS groups, AIDS specialists and researchers have declined my invitation to engage in a public dialogue on the validity of the HIV/AIDS hypothesis, the accuracy of HIV tests, and the safety and efficacy of AIDS treatment drugs. Their names are posted on the Alive & Well Alternatives website at http://www.aliveandwell.org .

 

Can Popular Consensus Be Wrong?

Throughout history, the medical and scientific communities have been in near unanimous agreement on causes and treatments for diseases that turned out to be absolutely wrong. Mass consensus on incorrect theories has often impeded vital research, delayed the development of cures or effective therapies for many conditions, and cost countless lives.

A number of medical protocols once deemed the standard of care have later proved to be harmful, and even deadly. For example, the 1899 edition of the Merck Manual, the prestigious medical text physicians worldwide regard as their bible, officially recommends poisons such as arsenic, ether, chloroform, turpentine oil, mercury, and strychnine as treatment for anemia, constipation, earaches and headaches.183 Before modern-day doctors agreed that exposure to X-rays and other forms of radiation cause genetic damage and cancers, radiation was routinely administered for tonsillitis, acne, ringworm, and enlarged lymph and thymus glands.184

DES (Diethylstilbestrol), a synthetic hormone given in the 1950s to prevent miscarriages in pregnant women was later found to cause cervical cancer and sterility in the daughters of women who used it.185 Thalidomide, a popular sleeping aid prescribed during the same era was banned after it caused limb deformities in many babies born to women taking the drug.186

During the 1960s and 70s, an entire epidemic was caused by Clioquinol, a widely used prescription medicine for diarrhea. For 15 years, doctors and scientists blamed a virus for the sudden outbreak of a new intestinal disorder and gave suffering patients the very drug that was the cause of their illness. By the time a minority view was considered and the drug responsible for the epidemic was finally banned, thousands had died and many victims were left blind or paralyzed.187

The earning power of "annuity medicines"drugs used throughout a lifetime to control symptoms wields great influence over healthcare consensus today. To take just one example, stomach ulcers have been traditionally blamed on stress, diet or excess acid. For fifty years, doctors routinely prescribed antacid drugs for temporary relief, drugs that usually prompt the stomach to produce more acid. Surgery to remove portions of the stomach or to cut sensitive stomach nerves was the state of the art in ulcer treatment until the 1976 arrival of Tagamet, a pharmaceutical that blocks acid secretion.188 By 1980, annual sales of Tagamet had reached $600 million, inspiring Fortune magazine to call it "one of the most stunningly successful products in the history of American business." In 1981, a similar drug Zantac was approved for use, and since 1988, has been the biggest selling drug in history.189 Neither drug gets rid of ulcers which remain a chronic, but more manageable problem. In fact, profits from treating the ongoing symptoms of ulcers may be preventing access to a simple, inexpensive cure discovered more than 15 years ago: A two-week course of antibiotics that kill the H pylori bacteria responsible for 80% of ulcers. Since doctors rely on drug companies for treatment updates and continuing education, and the drug companies are not promoting the new findings, patients and healthcare practitioners remain unaware of the important breakthrough.190

 

 

Conventional Wisdom: Words from the Mainstream

 

"There is no definitive peer-reviewed scientific literature on the long term efficacy of protease inhibitors, yet it would be criminal not to use them."

Dr. Charles Carpenter, Director, International Health Institute,
Brown University, Rolling Stone, March 6, 1997

 

"Important safety information: About 5% (5 in 100) of patients who take ZIAGEN have a serious allergic reaction that may result in death. If you have skin rash or two of the FOLLOWING SYMPTOMS, STOP TAKING ZIAGEN AND CALL YOUR DOCTOR IMMEDIATELY: fever, nausea, vomiting, diarrhea or abdominal pain, severe tiredness, achiness, or generally ill feeling...

"The most common side effects of ZIAGEN are skin rashes, fever, nausea, vomiting, diarrhea, abdominal pain, tiredness, muscle and joint pain, generally ill feeling...Most of these side effects do not cause people to stop taking ZIAGEN."

Glaxo-Wellcome ad for the anti-HIV drug ZIAGEN, March 1999

 

"If the virus doesn't get you, the drugs you take will."

Steve Gendin, Contributing Editor, POZ magazine, January 1999

 

"One of the major barriers to effectively treating HIV is that most people do not feel sick at the time they are offered anti-HIV medications. In fact, it is only after starting the medications that they begin to feel sick."

Dr. Lori Swick, The Toronto Star, September 24, 1999

 

"Here we are, knocking down handfuls of drugs that nobody really knows a lot about...and as research keeps coming up with newer and better medications that we also don't know very much about, we'll take them anyway. We're knocking down chemicals that are totally, completely foreign to almost everyone, including nature...but with a little luck, a positive outlook, and good nutrition, health improvement will happen."

Jennifer Jensen, RD (deceased), Nutritional advisor for the AIDS organization
Being Alive, Women Alive Newsletter, September 1997

 

"Some new AIDS drugs are beginning to produce serious toxic conditions in patients: an increased prevalence of premature heart disease, a serious form of obesity known as lipodystrophy, and liver disease. What we have is a tremendous improvement over what we used to have, but we must find ways to reduce life-threatening toxicity. That's why the search for a cure for AIDS, however unlikely, should not be given up."

Dr. Joep Lange, AIDS treatment specialist,
The Globe and Mail, May 4, 1999

 

"Failures are occurring right and left...They aren't dying of traditionally defined AIDS illnesses. I don't know what they're dying of...but they're just wasting and dying. While we are making good guesses, they are just guesses. We don't know what we are doing."

Dr. Michael Saag, AIDS researcher, University of Alabama at
Birmingham, Esquire magazine, April 1999

 

"When there wasn't effective [AIDS] treatment, money being wasted didn't matter so much."

Michael Weinstein, founder of the $45 million nonprofit AIDS organization AIDS
Health Care Foundation, The Wall Street Journal, December 20, 1996

 

"If the spread of HIV continues, by 2001 there could be ten billion people infected hypothetically...however the population of the world is only five billion. Could we be facing the threat of extinction during our lifetime?"

Theresa Crenshaw, President's AIDS Commission, 1987,
SPIN magazine, June 1995

 

"Remember the APLA position: HIV is a necessary but not sufficient cause of AIDS."

Lee Klosinski, Education Division, AIDS Project Los Angeles,
memo to Speaker's Bureau volunteers, April 1993

 

"Question for Class Discussion: You have just read some of the evidence for and against HIV being the cause of AIDS. Assuming you agree with the vast majority of HIV/AIDS investigators worldwide, that HIV does cause AIDS, do you think there comes a time at which dissenters forfeit their right to make claims on other people's time and trouble by the poverty of their arguments and by the wasted effort and exasperation they have caused?"

AIDS Update 1999, a college textbook by
Gerald J. Stein, PhD, Prentice Hall Inc.

 

"We don't know what the long-term effects of AZT use during pregnancy might be, but so far we have seen virtually no adverse effects in the short term...Not one single tumor. Not one...I mean [the children] have cancers, lymphomas, and other problems like that...but there's no reason to link those cancers to AZT."

Dr. Ellen Cooper, Principal researcher of the Women and Infants Transmission Study,
Mothering magazine, September/October 1998

 

"I know we've seen some webbed fingers...but these birth defects are cosmetic and don't interfere with life."

Mary Caffrey, Nurse-practitioner, Pediatric Division of the University of
San Diego Medical Center, on AZT-generated birth defects,
Zenger's, Issue 63, September 1999

 

"We are still very confused about the mechanisms that lead to CD4 T cell depletion, but at least now we are confused at a higher level of understanding."

Dr. Paul Johnson, Harvard Medical School, Science magazine, May 1997

 

"The diagnostic criteria accepted by the AIDS surveillance case definition should not be interpreted as the standard of good medical practice."

US Centers for Disease Control, Journal of the American
Medical Association, September 4, 1987 p1149

 

"Sometimes we virologists have a virus in search of a disease."

Dr. Robert Gallo, Virus Hunting, Basic Books, 1991

 

"An AIDS vaccine should be ready for testing in about two years."

Margaret Heckler, Head of Health and Human Services, April 24, 1984

 

"Newark and New Jersey have begun casting their nets for test subjects for the world's first full-scale clinical trials of an AIDS vaccine. AIDSVax is a genetically engineered drug...that triggers [HIV] antibodies that may enable a person to better protect himself as soon as he is exposed to the real virus, before the immune system is devastated. Dr. Krim of AmFar said 'AIDSVax is worth a try. And even if it is ineffective, it will be a good rehearsal on how to recruit for and test other vaccines.'"

The New York Times, June 8, 1999


 

Public Health, Public Relations, and AIDS

After nearly two decades of warnings about the impending heterosexual AIDS epidemic, none has materialized. In contrast to the dire predictions and despite widespread HIV testing, AIDS has remained almost exclusively confined to the original risk groups.172 Even within risk groups, the numbers have never reached expected proportions and have been quietly diminishing for over five years. As AIDS in America has failed to live up to its terrifying reputation, our attention is directed to other parts of the world where harrowing estimates go unchecked and vastly exceed actual diagnoses.173

Information from the US Centers for Disease Control reveals that the disparity between official AIDS reports and actual AIDS data began in 1987. At that time, public health agencies elected to ignore their own findings in favor of promoting the notion that "everyone is at risk for AIDS."174,175 Although epidemiology indicated this claim was not and would probably never be true, marketing research concluded that widespread support for AIDS would be impossible unless AIDS was considered a widespread health threat. Responding to Gallup Polls and PR studies, the CDC decided on a strategy that disregarded the facts in order to "mobilize support for public funding."175 As CDC virologist Dr. Walter Dowdle admitted, "As long as this was seen as a gay disease, or even worse, a disease of drug abusers, this pushed the disease way down the ladder" of funding priorities.

The CDC's early decision to overestimate AIDS and magnify the risks launched one of the most successful advertising campaigns in history. In 1986, the majority of Americans did not feel at risk for AIDS; by 1988 more than two-thirds thought a full scale epidemic was likely, and by 1991, most believed that even married couples faced a substantial risk of contracting AIDS.175 Federal tax dollars allocated to AIDS doubled the first year of the CDC ad campaign, and by the early 90s had topped $1 billion a year.

While concern and support for AIDS has multiplied and spread among millions of Americans, AIDS itself has not. This discrepancy has required a careful management of information and the need for constant advertisements, predictions and news reports that perpetuate ideas about AIDS that are out of sync with reality. Instead of revealing hard numbers and cold facts, most public health and AIDS organizations, along with the media, dispense reports that employ misleading percentages, alarming estimates, or cumulative totals for AIDS that disguise the realities of the epidemic.

The use of cumulative totals makes it possible to cite ever-growing numbers for AIDS even as AIDS is actually declining. Until 1997, despite steady decreases that began four years earlier, AIDS in America was almost universally described as an increasing problem, an image supported by the use of cumulative case numbers. For example, the total of new adult AIDS cases in the US in 1996 was 5,000 less than in 1995, but by adding the 1996 cases to the total number of cases reported since 1981, the decline of 5,000 was portrayed as an increase.176

Percentage calculations can turn drops into rises and are frequently used to make small numbers appear impressive. For example, in 1998 the number of new cases of AIDS among women decreased by more than 2,000, but at the same time, the percentage of total cases that women represent increased by 1%. This 1% difference in percentage is used to make the claim that AIDS is increasing among women.176 The warning that heterosexuals are the fastest growing AIDS risk group is based on this same misleading use of percentages. In fact, cases of AIDS have been declining in all risk groups since 1993.177

Such statistical sleight of hand is not exclusive to the US media or American AIDS organizations. In Canada, a nation with an extremely low incidence of AIDS, government AIDS officials and the media play up the few cases there are and often perform their own magic with the numbers. For example, in 1995 new AIDS diagnoses among Canadian women totaled 175. This figure dropped to 165 in 1996, and then to 88 in 1997. News reports did not celebrate these decreases or the fact that in a country with some 15 million females, only 88 women were diagnosed with AIDS that year. Instead, the increased percentage of cases among women, from 8.8% of all AIDS cases in 1995 to 15.4% of AIDS cases in 1997, led Canada's Laboratory Centre for Disease Control (LCDC) to pronounce that women with AIDS made up "the highest proportion [of AIDS cases] observed since monitoring of the epidemic began."178

Estimates that can make anything seem possible are commonly used in AIDS news reports and advertising campaigns, and although the word "estimate" is crucial to qualifying claims, it is often omitted from ads and media reports. To take just one example, advertisements for the "Until There's A Cure" AIDS bracelet use blood-red capital letters to proclaim "16,000 people a day are introduced to HIV by testing positive."179 It is necessary to contact the bracelet company in order to learn that the figure cited in the ad is an approximation based on global WHO estimates which are not even based on HIV test results.180

WHO estimates for AIDS in developing areas of the world such as Africa are the basis for many news reports. Although these estimates bear little resemblance to actual numbers of AIDS cases, the discrepancy might understandably be explained by the need to estimate a certain amount of AIDS cases in undiagnosed persons. However, the ratio of diagnosed cases to estimated cases inexplicably varies among African nations, ranging from nine estimated AIDS cases for every one case diagnosed, to as high as 69 for each single case.181 For example, the WHO ratio for AIDS in Zimbabwe is 10/1, while the ratio of 48/1 is used next door in Mozambique, which changes to 33/1 across the border in neighboring South Africa.

Estimates are often combined with predictions, a mix that can produce particularly spectacular results. One recent example is a Reuters news release that announced "China has an estimated 400,000 people with HIV although confirmed cases [since the beginning of the epidemic] are only about 11,000." In this same report, "unidentified experts" went on to predict that these 11,000 cases could grow to "one million by the end of next year."182

References

All referenced text is excerpted from the 4th edition (second printing) of the book What If Everything You Thought You Knew About AIDS Was Wrong? and wherever possible, has been updated for this web site.

  1. In the United States, AIDS = 28 old illnesses and one non-illness:
    1983 original AIDS definition (12 illnesses): Pneumocystis carinii pneumonia, Kaposi's sarcoma, toxoplasmosis, strongyloidosis, aspergillosis, cryptococcosis, candidiasis, cryptosporidiosis, cytomegalovirus, herpes simplex, progressive multifocal leukoencephalopathy, lymphoma of the brain
    1985 revised definition (seven more old illnesses added): Mycobacterium avium complex, histoplasmosis, isosporiasis, Burkitt's lymphoma, immunoblastic lymphoma, candidiasis of the bronchi, trachea and lungs, and a positive HIV antibody test.
    1987 revised definition (six additional illnesses): Encephalopathy, Mycobacterium tuberculosis, wasting syndrome, coccidioidomycosis, cytomegalovirus retinitis, Salmonella septicemia. HIV antibody test no longer required.
    1993 revised definition (three more illnesses plus one surrogate marker): Recurrent bacterial pneumonia, invasive cervical cancer, pulmonary tuberculosis, T Cell count of <200 or <14% of total lymphocytes (non-illness).
    Source: Duesberg P, Yiamouyannis J, 1995 AIDS: The Good News Is HIV Doesn't Cause It Health Action Press

  2. US Centers for Disease Control 1994 HIV/AIDS Surveillance Report Year-end edition 1993

  3. Navarro M AIDS Definition Widened to Include Blood Cell Count August 8 1993 New York Times; Altman L AIDS Cases Increase Among Heterosexuals March 11 1994 New York Times

  4. US Centers for Disease Control HIV/AIDS Surveillance Report Year-end editions 1998, 1997, 1996, 1995, 1994, 1993

  5. US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end edition 1997 Table11 p17

  6. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end edition 1998 p43

  7. Duesberg P 1993 The HIV Gap in National Statistics Bio/Technology 11:955-6

  8. Laboratory Centre for Disease Control, Health Canada, 1998 HIV and AIDS in Canada: Surveillance Report to December 31, 1997; US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998

  9. US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end edition 1997 Figure 6 p25; US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end edition 1998

  10. World Health Organization 1985 Bangui definition for AIDS in Africa (current use confirmed by WHO April 1999); WHO case definitions for AIDS surveillance in adults and adolescents, Weekly Epidemiological Record September 1994; 69:273-80 (current use confirmed by WHO April 1999)

  11. Duesberg P 1996 Inventing the AIDS Virus: Regnery Press, Washington DC p141-145

  12. Duesberg P 1996 Inventing the AIDS Virus: Regnery Press, Washington DC p54-58

  13. Carins J 1978 Cancer: Science and Society WH Freeman and Company, San Francisco

  14. Duesberg P, Rasnick D 1998 The AIDS Dilemma: Drug Diseases Blamed on a Passenger Virus Genetica 104:85-132; Mullis K 1998 Dancing Naked in the Mindfield Pantheon Books, New York p171-190; Shenton J 1998 Positively False St Martin's Press, New York p6-17

  15. Mullis K 1988 Dancing Naked in the Mindfield Pantheon Books, New York p 178; Duesberg P 1996 Inventing the AIDS Virus Regnery Press, Washington DC p 89-96

  16. Altman L New York Times, April 23 1984

  17. Altman L Researchers Believe AIDS Virus is Found New York Times, April 24 1984 (Dr. James Curran, head of the CDC's AIDS investigating team, calls discovery "the virus that causes AIDS") 

  18. Gallo found HIV in only 26 of 63 AIDS patients (41%) Source: Gallo R May 4 1984 Science Volume 224 p502

  19. In 1983, Montagnier sent Gallo "retrovirus particles" (LAV) taken from the lymph node of a male homosexual without AIDS. Source: Science May 20 1983, Vol 220; the virus Gallo claimed to have discovered in 1984 was found to actually be Montagnier's LAV. Source: New Scientist, February 12 1987

  20. Dingell J Misconduct in Medical Research, New England Journal of Medicine 1993 328:1610-1615; Co-Discoverer of HIV Loses Bid to Regain Job AIDS Policy and Law May 14 1999 Vol 14 No 9; Crewdson J In Gallo Case, Truth Termed a Casualty: Science Subverted in AIDS Research Chicago Tribune, January 1 1995

  21. Baffour A Are 26 Million Africans Dying of AIDS? December 1998 New African Magazine p34-42

  22. Duesberg P Inventing the AIDS Virus Regnery Press, Washington DC; Root-Bernstein R 1993 Rethinking AIDS The Free Press, New York

  23. Cordes R, et al 1995 Pitfalls in HIV Testing Postgraduate Medicine 98:177; Langedijk J, et al 1992 Identification of Cross-reaction Epitopes Recognized by HIV-1 False-positive Sera AIDS 6:1547-1548; Strandstrom H, et al 1990 Studies with Canine Sera that Contain Antibodies which Recognize HIV Structural Proteins Cancer Research, September 1:50(17 Suppl):56285-56305; Germanson T 1989 Screening for HIV: Can We Afford the Confusion of the False Positive Rate? Journal of Clinical Epidemiology 42:1235; Weiss R, et al 1988 HIV Testing is the Answer-What's the Question? New England Journal of Medicine 319:1010-1012; Burke, et al 1988 Measurement of the False Positive Rate in a Screening Program for HIV Infections New England Journal of Medicine 319(15):961-964; US News and World Report, November 23 1987 p22c; Jackson G, et al 1988 Passive Immunoneutralisation of Human Immuno-deficiency Virus in Patients with Advanced AIDS Lancet, September 17:647

  24. Papadopulos-Eleopulos E, et al 1993 Is a Positive Western Blot Proof of HIV Infection? Bio/Technology Journal Vol 11 p696-707

  25. Papadopulos-Eleopulos E, et al 1993 Has Gallo Proven the Role of HIV in AIDS? Emergency Medicine 5:113-123

  26. Papadopulos-Eleopulous E, et al 1993 Is a Positive Western Blot Proof of HIV Infection? Bio/Technology Vol. 11

  27. Strandstrom H, et al 1990 Studies with Canine Sera which Recognise HIV Structural Proteins, Cancer Research 50:5628s-5630s. Source: Testing, Testing, 1,2,3... Turner V 1996 Contiuum Vol 3:5 p8-11

  28. Papadopolus-Eleopulos E, et al 1993 Is a Positive Western Blot Proof of HIV Infection? Bio/Technology Journal Vol 11 p696-701; Quantum Clinical Laboratory, Los Angeles, CA: HIV antibody test results for Christine Maggiore April 9 1992 HIV reactive, WB positive positive; March 27 1993 HIV reactive, WB indeterminate; September 1 1993 HIV non-reactive

  29. Abbott Laboratory's ELISA HIV antibody test kit pamphlet

  30. Continuum Vol 3:4 with thanks to Val Turner, Royal Perth Hospital, Australia; Bio/Technology June 1993 11:696-707

  31. Roche Amplicor PCR Diagnostics HIV-1 Monitor test kit pamphlet

  32. Curran J 1985 The Epidemiology of AIDS: Current Status and Future Prospects Science 229:1352-1357; Karon, et al 1996 Prevalence of HIV Infections in the US Journal of the American Medical Association 276:126-131; Krieger L One in 300 US Adults Infected, San Francisco Examiner July 7 1996 pA82

  33. NBC Nightly News, March 10 1995: Robert Hager of NBC reported that the CDC was about to lower estimates they knew were too high. CDC spokesperson Michelle Bond remarked that the CDC officials were reluctant to report lower numbers for fear of adverse budgetary consequences.

  34. All STDs except genital herpes: US Centers for Disease Control 1997, Table 1: Cases of STDs reported by state health departments in US 1941-1997, STD Surveillance p65-66. Genital herpes: Meyer T March 24 1998 Associated Press, Atlanta (Meyer quotes CDC and Dr. Charles Bell of Texas Department of Health)

  35. US Centers for Disease Control 2003 HIV/AIDS Surveillance Report Year-end edition 2002 (Deaths in persons with AIDS, cumulative totals through December 2002)

  36. US Centers for Disease Control HIV/AIDS Surveillance Report Year-end edition states "Reported deaths are not necessarily caused by HIV-related disease"

  37. CDC Wonder website; The New York Times, death count, all ages, all races, both genders 1981-2002

  38. Lazarou J, et al 1998 Incidence of Adverse Drug Reactions in Hospitalized Patients (1966-1996) Journal of the American Medical Association, 279:1200; Manmaney T Medications Kill 100,000 Annually Los Angeles Times April 15 1998; CDC Wonder website 2004

  39. PBS 1998 The American Experience: Influenza 1918

  40. World Health Organization Weekly Epidemiological Record November 2001 (current)

  41. UNAIDS June 1998 Report on the Global Epidemic; World Health Organization June 1998, Weekly Epidemiological Record

  42. CDC National Vital Statistics Report October 7 1998, Vol 47:4 Table E p7 (Deaths and death rates, final 1996 and preliminary 1997)

  43. Geshekter C 1997 AIDS: The Leading Cause of Unjustified Hysteria, Reappraising AIDS, February Vol 5:2

  44. Institute of Medicine (IOM) 1996 Scientific Opportunities and Public Needs; Webster K Disproportionate Funding Associated Press June 16 1999

  45. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end edition 1998

  46. Crowne D, et al 1964 The Approval Motive John Wiley and Sons, New York; Saxe L 1991 Lying: Thoughts of an Applied Social Psychologist American Psychologist 46:409-415; Source: Brody S Sex at Risk Transaction Publishers, New Brunswick

  47. Brody, S 1997 Sex at Risk Transaction Publishers, New Brunswick; 80%: Potterat, et al 1987 JAMA 256 p 12; 65%: Renzullo, et al 1990 JAIDS 3, p266-271; 83%-90%: Committee on AIDS Research and the Behavioral, Social, and Statistical Sciences 1989; 69%: Chicago Dept of Public Health, Journal of AIDS 1997; 99.4%: NYC Dept of Health, American Journal of Epidemiology 137:2

  48. Figures for AIDS by Risk Groups are based on cumulative figures through 1998 and do not include cases where risk status was not assessed; AIDS by Health Status are for years 1993 through 1997 using Table 11 of the 93-97 US CDC HIV/AIDS Surveillance Reports (1997 was the last year the CDC published the data in Table 11); AIDS by Gender is based on cumulative figures through 1998

  49. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998

  50. Burke D, et al 1990 Seroprevalence Among Applicants for US Military Service Unpublished data through 1997 from US Military Processing: For a copy of this unpublished data, send a SASE to the author

  51. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998 p26

  52. Duesberg P 1996 Inventing the AIDS Virus Regnery Press, Washington DC p183

  53. Holding R, Carlsen W 1998 Epidemic Ravages Caregivers San Francisco Chronicle p1, A6-A8

  54. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998 Table 7 p14; US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end 1997 Table 8 p15

  55. Laboratory Centre for Disease Control, Health Canada, April 1998 Gonorrhea in Canada; US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end 1997, Tables 13A and 13B; Interview with LCDC Bureau of AIDS and STDs Office of Don Sutherland, September 14, 1998: Gonorrhea cases in Canada

  56. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998 Table 7 p14; US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end 1997 Table 8 p15

  57. Mok, et al 1987 Infants born to Mothers Seropositive for HIV Lancet 1164-1168; European Collaborative Study 1991 Children Born to Women with HIV 1 Lancet 337:253-260

  58. Source: National Center for Health Statistics July 1996 703/821-8955: Cumulative SIDS deaths in children under 1 year of age 1983-1996, 1997 preliminary, 1981-1982 computed by average of years 1983-1993

  59. Transactions of the Society of Actuaries, Vol XLIV p333-97; Boffey P April 22 1988, Researchers List Odds of Getting AIDS in Heterosexual Intercourse New York Times; Hearst N, Hulley S April 1988 Journal of the American Medical Association; Dangers Real and Imagined December 8 1997 Wall Street Journal; Discover magazine, May 1996 p82

  60. World Health Organization, November 1998 Weekly Epidemiological Record (current)

  61. Harvard University Global Burden of Disease Study, 1996; World Health Organization, Geneva 1996 Fighting Disease, Fostering Development; Geshekter C Rethinking AIDS in Africa Reappraising AIDS Vol 3:2 February 1995

  62. World Health Organization 1985 Bangui definition for AIDS in Africa (in current use); WHO case definitions for AIDS surveillance in adults and adolescents Weekly Epidemiological Record September 1994 69:273-80 (confirmed April 1999 by WHO)

  63. World Health Organization, November 1998 Weekly Epidemiological Record (current); Harvard University Global Burden of Disease Study, 1996; World Health Organization, Geneva 1996 Fighting Disease, Fostering Development; Geshekter C Rethinking AIDS in Africa Reappraising AIDS Vol 3:2 February 1995; World Health Organization 1985 Bangui definition for AIDS in Africa (in current use); WHO case definitions for AIDS surveillance in adults and adolescents Weekly Epidemiological Record September 1994 69:273-80 (confirmed April 1999 by WHO); World Health Organization World Health Report 1998 Annual cases of selected diseases

  64. Kestler H, et al 1990 Induction of AIDS in Rhesus Monkey by Molecularly Cloned SIV Science 2448:1109-112; Kestler, et al 1991 Importance of Net Gene for Maintenance of High Virus Loads Cell 65:651-662; Fultz, et al 1990 Humoral Response to SIV/SMM Infection in Macaque and Mangabey Monkeys Journal of AIDS 3:319-329; Weiss R, et al 1985 Molecular Biology of RNA Tumor Viruses Cold Spring Harbor Press, New York; Blatner W, et al 1988 HIV Causes AIDS Science 241:514-515; Lambrou E 1994 AIDS Scare or Scam p14-15 Vantage Press, New York

  65. Gao, et al Nature February 4 1999

  66. World Health Organization, November 1998 Weekly Epidemiological Record (current)

  67. Russell R Kenya Slow to Face Up to AIDS Scourge Reuters November 25 1998

  68. World Health Organization World Health Report 1998

  69. World Health Organization World Health Report 1998 Annual cases of selected diseases

  70. Journal of AIDS 1994 7:8 p876

  71. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998; 9(2) Calculations: David Crowe, Alberta Reappraising AIDS Society

  72. US Centers for Disease Control HIV/AIDS Surveillance Report Year-end editions 1997, 1996, 1995, 1994, 1993 (AIDS indicator conditions reported by age group, United States)

  73. US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end 1997 p25 Figure 6

  74. US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end 1997 p25 Figure 6

  75. POZ magazine July 1999: Glaxo-Wellcome Ad for Ziagen (abacavir sulfate), December 1998 MG-001; Merck Ad for Crixivan (indinavir) Merck and Co, Inc. 1998 99-4084; Roxanne Ad for Viramune (nevirapine) July 1999, RX-2140 (4/98); Glaxo-Wellcome Ad for Combivir (lamivudine/zidovudine) March 1999

  76. POZ magazine July 1999: Glaxo-Wellcome Ad for Combivir

  77. Hammer S, et al 1997 A Controlled Trial of Two Nucleoside Analogues Indinavir in Persons with HIV New England Journal of Medicine 337:725-733 

  78. Merck Ad for Crixivan (indinavir) Merck and Co, Inc. 1998 99-4084

  79. POZ magazine July 1999: Glaxo-Wellcome Ad for Ziagen (abacavir sulfate), December 1998 MG-001; Merck Ad for Crixivan (indinavir) Merck and Co, Inc. 1998 99-4084; Roxanne Ad for Viramune (nevirapine) July 1999, RX-2140 (4/98); Glaxo-Wellcome Ad for Combivir (lamivudine/zidovudine), March 1999; FDA Advisory (warning of spontaneous bleeding in 15 hemophiliacs using protease inhibitors), July 16 1996; Dube M, Johnson D, et al 1997 Protease Inhibitor Associated Hyperglycemia Lancet 350:713-4; Kotler D Truncal Obesity February 20 1998 Clinical Care Options for HIV (Monthly Experts Column); Garrett L The Virus at the End of the World Esquire March 1 1999; Lo J, et al 1998 Buffalo Hump in Men with HIV-1 Lancet March 21 1998 p867-870; Miller KD, et al Visceral Abdominal Fat Accumulation Associated with Use of Indinavir p871-875; Kim L FDA Approves Another Protease Inhibitor The Atlanta Journal and Constitution April 17 1999 p2E; Mickleburgh R, Study AIDS Drugs Long Term, Makers Told The Globe and Mail (Canada) May 4 1999; Colebunders E, et al Sexual Dysfunction with Protease Inhibitors Lancet 353 May 22 1999; Waldholz M, Tanouye E Cocktail Break Wall Street Journal January 25 1999

  80. James Curran on CNN, August 23 1998 8:00 pm EST

  81. Altman L New Cases Widen Views About AIDS New York Times January 5 1984

  82. Auberbach, et al 1984, Am J Med 76:487; Boffey P AIDS in the Future: Risk of Developing AIDS New York Times January 14 1986; JAMA 262: 3129-3130; Burkett E HIV: Not Guilty? Miami Herald December 23 1990 p12-17

  83. Eckholm E Onset of AIDS After Transfusion Found to Lag Average of 5 Years, New York Times May 29 1986; Lambrou E 1994 AIDS: Scare or Scam? Vantage Press, New York p15; Garrett L June 1999 Blacks May Have Genetic Risk of HIV Infection, Alive & Kicking!; Waldholz M, Tanouye E Cocktail Break Wall Street Journal January 25 1999

  84.  

  85. Johnson C, Philpott P Viral Load of Crap Reappraising AIDS Vol 4:10 October 1996; Duesberg P 1995 Nature 357 p197

  86. Rasnick D Kinetics Analysis of Consecutive HIV Proteolytic Cleavages of the Gag-Pol Polyprotein Journal of Biological Chemistry March 7 1997

  87. Mullis K October 1998 The Medical Establishment vs. The Truth Penthouse Magazine

  88. Rich J, et al 1999 Misdiagnosis of HIV Infection by HIV-1 Plasma Viral Load Testing: A Case Series Annals of Internal Medicine 130:37-39; Sullivan, et al Persistently Negative HIV-1 Antibody Enzyme Immunoassay Screening Results for Patients with HIV-1 Infection and AIDS AIDS January 14 1999 13:89-96

  89. Piatak M March 19 1993 High Levels of HIV-1 in Plasma During All Stages of Infection Determined by Competitive PCR Science 259:1749-53; Roehr B Loading Zone POZ Magazine August 1999 p76

  90. New England Journal of Medicine November 3 1994 331:18 p1176-1177

  91. Semba R, et al 1993 Increased Mortality Associated with Vitamin A Deficiency During HIV-1 Infection Arch Intern Med 153:2149-2154

  92. WHO/UNAIDS, 1998 HIV and Infant Feeding: A Guide for Health Care Managers and Supervisors FRH/Nut 98, 22

  93. HealthNews Mothering magazine Summer 1997 p40; Dew J October 8 1999 Newborn HIV Tests Criticized New Haven Register

  94. Farber C AZT Roulette: The Impossible Choices Facing HIV Positive Mothers Mothering magazine September/October 1998 Issue 90

  95. Semba R, et al 1993 Increased Mortality Associated with Vitamin A Deficiency During HIV-1 Infection Arch Intern Med 153:2149-2154

  96. Kumar R, et al 1994 Zidovudine Use in Pregnancy: A Report on 104 cases and Birth Defects Journal of AIDS 7(10):1034-1039

  97. Cordes R, et al 1995 Pitfalls in HIV Testing Postgraduate Medicine 98:177; Ng V, et al Serological Diagnosis with Recombinant Peptides/Proteins Clinical Chemistry 37:1667-1668; Profitt M, et al 1993 Laboratory Diagnosis of HIV Infection Inf Dis Clin North Am 7:203; Steckelberg J, Cockerill F 1988 Serologic Testing for HIV Antibodies Mayo Clinic Proc 63:373; Voevodi A 1992 HIV Screening in Russia Lancet 339:1548

  98. Mothering magazine Summer 1997 Health News p40

  99. Cleary, et al 1987 Journal of the American Medical Association 258(13):1757-62

  100. US Centers for Disease Control Recommendations of the US Public Heath Service Task Force on the Use of Zidovudine [AZT] to Reduce Perinatal Transmission of HIV Morbidity and Mortality Weekly Report Vol 43 No RR-11 August 5 1994

  101. Regush N No AZT For My Baby, Please http://ABCNews.com September 16 1999

  102. Gwarteny D Baby's Risk for HIV Sparks Fight The Oregonian January 31 1999; Wright J Court Grants Delay in Baby HIV Case The Register-Guard February 5 1999

  103. Good Morning America September 9 1998

  104. Philpott P Maine Mother Wins Court Fight Against HIV Doctors Reappraising AIDS Vol 6 October 10 1998

  105. Mother Wins Right to Stop HIV Drugs New York Times April 20 1999; Dateline NBC January 25, 1999; A Mother's Instinct People Magazine October 5 1998 p157-158

  106. News Broadcast, CJOB 68 August 18 1999; PeritzI Mother Fights to Block Son's HIV Drug Therapy The Globe and Mail (Canada) August 18 1999

  107. McKittrick A Ethical Drug Pricing: An Oxymoron? Provincetown Positive Spring 1999 p37-39

  108. Duesberg P 1996 Inventing the AIDS Virus Regnery Press, Washington DC p 309-359

  109. Physicians Desk Reference 1994 p32

  110. Duesberg P 1996 Inventing the AIDS Virus Regnery Press, Washington DC p 309-359

  111. Lauritsen J 1993 The AIDS War Askelpios, New York, FDA Documents Show Fraud in AZT Trials p381-397

  112. Lancet 1993 343:871, Concorde Coordinating Committee; Journal of the American Medical Association 1988 203:3009; New England Journal of Medicine 1992 326:437. Source: Hand T Why Antiviral Drugs Cannot Resolve AIDS Reappraising AIDS Vol 4:9 September 1996

  113. Source: Interview with Dr. Charles Thomas in video HIV=AIDS: Fact or Fraud? Starvision Productions (Stephen Allen, prod.) Denver CO; Duesberg P 1996 Inventing the AIDS Virus Regnery Press, Washington DC p 309-359

  114. British Medical Journal July 15 1995 p156-158 (49%); Science Magazine February 24 1995 p1080 (34%); JAMA 260:3009 1988; New England Journal of Medicine 1992, 326:437. Source: Hand T Why Antiviral Drugs Cannot Resolve AIDS Reappraising AIDS Vol 4:9 September 1996

  115. Merck Manual 1992 16th edition p55, Merck Research Laboratories; Glaxo-Wellcome information sheet accompanying Zidovudine

  116. Hammer S, et al 1997 A Controlled Trial of Two Nucleoside Analogues Indinavir in Persons with HIV New England Journal of Medicine 337:725-733

  117. Merck ad for Crixivan A&U magazine July 1999 99-4084 910 (508) CRX

  118. Anderson M The Big Tease Valley Advocate February 20 1997

  119. Interview with Christine Maggiore September 1997

  120. AIDS expert Dr. Bruce Walker on ABC News Nightline May 19 1999 11:35 PM EST

  121. Ostrom N The New York Native July 15 1996 Issue 691

  122. POZ magazine July 1999: Glaxo-Wellcome Ad for Ziagen (abacavir sulfate), December 1998 MG-001; Merck Ad for Crixivan (indinavir) Merck and Co, Inc. 1998 99-4084; Roxanne Ad for Viramune (nevirapine) July 1999, RX-2140 (4/98); Glaxo-Wellcome Ad for Combivir (lamivudine/zidovudine) March 1999

  123. Journal of the American Medical Association July 10 1996

  124. Johnson H Rolling Stone Magazine Special Report: Dr. David Ho and the Lazarus Equation March 6 1997

  125. Levy J 1996 AIDS Surrogate Markers: Is There Truth in Numbers? JAMA Vol 276 p161-162

  126. Merck ad for Crixivan A&U magazine July 1999 99-4084 910 (508) CRX

  127. Altman L New York Times February 2 1996; Garrett L Newsday March 5 1996; The Boston Globe February 1 1999

  128. Dr. Raymond Schinazi of Emory University, Atlanta, Georgia. Source: Garrett L Newsday March 31 1995

  129. Lancet June 1 1997 Vol 349 p1745; Associated Press Report, Philadelphia Inquirer June 13 1997; Anderson M The Big Tease The Valley Advocate February 20 1997; Green F Cocktail Hangover Cleveland Free Times May 5 1999 Vol 7 Issue 33; Signorile M 641,086 and Counting Out magazine September 1998

  130. The Morning After POZ magazine February 1997

  131. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998; 9(2) Calculations: David Crowe, Alberta Reappraising AIDS Society; US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end 1997 p25 Figure 6

  132. US Centers for Disease Control HIV/AIDS Surveillance Report Year-end editions 1997, 1996, 1995, 1994, 1993 (AIDS indicator conditions reported by age group, US)

  133. Interview with Christine Maggiore September 1997 

  134. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998; 9(2) Calculations: David Crowe, Alberta Reappraising AIDS Society; US Centers for Disease Control 1998 HIV/AIDS Surveillance Report Year-end 1997 p25 Figure 6

  135. Gallo R 1984 Science 224; Piatak M 1993 Science 259; Ho D 1991 New England Journal of Medicine 324:961; Shaw G 1991 New England Journal of Medicine 324:954; Cooper 1992 Lancet 341:1099

  136. Duesberg P 1996 Inventing the AIDS Virus Regnery Press, Washington DC p174-180

  137. Bialy H, Duesberg P March 1995 Letter to Nature. Source: AIDS: Virus or Drug Induced? Duesberg P (editor) 1996 Kluwer Academic Publishers, Netherlands

  138. Ho D, et al 1995 Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection Nature 373:123-126; Wei X, et al 1995 Nature 373:117-122

  139. Kary Mullis at HEAL Los Angeles, October 25 1995

  140. Philpott P, Johnson C 1996 Viral Load of Crap Reappraising AIDS Vol 4:10 p2

  141. Johnson C Viral Load and the PCR Continuum Vol 4:4 November/ December 1996

  142. CDC faxback document #320320 sent in reply to an inquiry by Christine Johnson

  143. Roche Amplicor PCR Diagnostics HIV-1 Monitor test kit pamphlet

  144. Defer C, et al 1992 Multicenter Quality Control of PCR Detection of HIV DNA AIDS 6:659-663; Bush, et al 1992, Journal of AIDS 5:872; Gerberding J 1994 Incidence and Prevalence of HIV, Hepatitis B, and CMV Among Health Care Personnel at Risk for Blood Exposure Journal of Infectious Disease 170:1410-1417; de Mendoza, et al 1998 False Positive for HIV Using Commercial Viral Load Quantification Assays AIDS 12:2076-2077; Rich J, et al 1999 Misdiagnosis of HIV Infection by HIV-1 Plasma Viral Load Testing: A Case Series, Annals of Internal Medicine 130:37-39

  145. Schwartz D, et al 1997 Extensive Evaluation of a Seronegative Participant in an HIV-1 Vaccine Trial as a Result of False-Positive PCR, Lancet Vol 350 No 9073 p256

  146. Rasnick D 1997 Kinetics Analysis of Consecutive HIV Proteolytic Cleavages of the Gag-Pol Polyprotein Journal of Biological Chemistry March 7 p6348-6353

  147. Piatak M, et al 1993 Science 259:1749-53

  148. Roderer M 1998 Getting to the HAART of T Cell Dynamics Nature Medicine Vol 4:2 p145-146; Levy J 1996 AIDS Surrogate Markers: Is There Truth in Numbers? JAMA Vol 276 p161-162

  149. Levy J 1996 AIDS Surrogate Markers: Is There Truth in Numbers? JAMA Vol 276 p161-162

  150. Philpott P, Johnson C 1996 Viral Load of Crap Reappraising AIDS Vol 4:10 p2

  151. Papadopulos-Eleopulos E, et al 1988 Reappraisal of AIDS: Is the Oxidation Induced by the Risk Factors the Primary Cause? Medical Hypothesis 25:151-162

  152. Papadopulos-Eleopulos E, et al 1993 Is A Positive Western Blot Proof of HIV Infection? Bio/Technology 11:696-707; Papadopulos-Eleopulos E, et al 1996 The Isolation of HIV: Has it Really Been Achieved? Continuum Vol 4:3 Supplement p1-24; Turner V 1996 Do HIV Antibody Tests Prove HIV Infection? Continuum 1996 Vol 3:5 p8-11; Papadopulos-Eleopulos E, Stewart G, et al 1997 HIV Antibodies: Further Questions and a Plea for Clarification Current Medical Research and Opinion 13:627-634

  153. Philpott P 1997 The Isolation Question Reappraising AIDS Vol 5:6 June/July/August

  154. Gallo R 1984 Science 224:497-508; Piatak M 1993 Science 259:1749-1754; Piatak M 1993 Lancet 341:1099; Daar, et al 1991 New England Journal of Medicine 324[14]:961-964; Clark, et al 1991 New England Journal of Medicine 324:954-960; Cooper, et al 1992 Lancet 340:1257-1258

  155. Nature Magazine May 26 1994

  156. Morning Report Los Angeles Times May 16 1996 F-2

  157. Project Inform letter to Dr. Bruce Alberts, President of the National Academy of Sciences, July 31 1997: Endorsements are for signers as of August 20 1997

  158. Letter to Christine Maggiore from Ric Parish, PLUS Programs Manager, May 30 1997

  159. Anderson MK 1997 Sick of It All The Valley Advocate January 15 1998

  160. Farber C 1995 AIDS Inc.: Observations of an AIDS Dissident Provincetown Positive April/May Issue p14-18

  161. Garrett L The Virus at the End of The World Esquire magazine March 1999

  162. A&U America's AIDS Magazine June 1999 Issue 56

  163. Duesberg P 1987 Retroviruses as Carcinogens and Pathogens: Expectations and Reality Cancer Research 47:1199-1220

  164. Interview with Christine Maggiore August 25 1999

  165. Eichenwald K, Kolata G Drug Trials Hide Conflicts for Doctors New York Times May 16 1999

  166. Smith M, Sticking Point: AIDS Vaccine Designed by Don Francis in Final Testing San Francisco Weekly July 14 1999

  167. CNN Website Massive Trial of AIDS Vaccine to Begin in Thailand February 10 1999 8:27 pm EST

  168. Dissecting Room Lancet Vol 353 May 15 1999 p1719

  169. McGinley L Price of Success: Powerful Treatments Create Growing Rift Among AIDS Groups Wall Street Journal December 20 1996

  170. Drug Money Counter Punch magazine July 1 1998

  171. Farber C 1995 AIDS Inc.: Observations of an AIDS Dissident Provincetown Positive April/May Issue p14-18

  172. US Centers for Disease Control HIV/AIDS Surveillance Report Year-end editions through 1998

  173. WHO website http://hivinsite.ucsf.edu/social/un/2098.3ce6.html Ratios of estimated AIDS cases/reported AIDS cases for African countries with highest estimated AIDS cases: Angola 22/1; Congo 13/1; Ethiopia 55/1; Kenya 9/1; Madagascar 69/1; Mozambique 48/1; Nigeria 35/1; South Africa 33/1; Uganda 37/1; Zimbabwe 10/1. For all African countries (with available data) combined, the ratio of estimated AIDS cases to reported AIDS cases is 16/1

  174. CDC national AIDS advertising campaign, October 1987: 38 TV commercials, 8 radio spots, 6 print ads

  175. Bennett A, Sharpe A Health Hazard: AIDS Fight Skewed by Federal Campaign Exaggerating Risks Wall Street Journal May 1996 p1

  176. Philpott P CDC Releases Data for 1995: What HIV/AIDS Epidemic? Reappraising AIDS Vol 4:7 July 1996

  177. US Centers for Disease Control HIV/AIDS Surveillance Report Year-end editions 1993 through 1998 with one exception: AIDS in teenage boys rose from 238 in 1994 to 245 in 1995

  178. Laboratory Centre for Disease Control, Health Canada, 1998 HIV and AIDS in Canada: Surveillance Report to December 31 1997 p1

  179. Until There's a Cure advertisement http://www.until.org

  180. Interview with Patty Dwyer from Until There's A Cure September 3, 1999 (800) 888-UNTIL

  181. WHO website Ratios of estimated AIDS cases/reported AIDS cases for African countries with highest estimated AIDS cases: Angola 22/1; Congo 13/1; Ethiopia 55/1; Kenya 9/1; Madagascar 69/1; Mozambique 48/1; Nigeria 35/1; South Africa 33/1; Uganda 37/1; Zimbabwe 10/1. For all African countries (with available data) combined, the ratio of estimated AIDS cases to reported AIDS cases is 16/1

  182. China Says HIV Cases Estimated at 400,000 April 1 1999 4:25 am EST Reuters, Bejing

  183. Merck Manual 1899 first edition

  184. Mendelsohn R 1984 How To Raise a Healthy Child In Spite of Your Doctor Ballentine Books, New York p13-15

  185. The American Medical Association Encyclopedia of Medicine Random House, New York p359; Mendelsohn R 1979 Confessions of a Medical Heretic Contemporary Publishing Company, Chicago p28-29

  186. The American Medical Association Encyclopedia of Medicine 1989 Random House, New York p 977

  187. Kono R 1975 The SMON Virus Theory Lancet ii:370-371; Shigematsu H, et al 1975 Epidemiological Approach to SMON Japanese Journal of Medicine, Science and Biology, 28 Supplement 23-33; Soda T 1980 Drug Induced Sufferings: Medical, Pharmaceutical and Legal Aspects Excerpta Medica: Amersterdam

  188. Marshall B Why Doctors Aren't Curing Ulcers Fortune Magazine June 9 1997

  189. Haney D Doctors Slow to Attack Bug Behind Ulcers Los Angeles Times (API) February 11 1996

  190. Marshall B Why Doctors Aren't Curing Ulcers Fortune Magazine June 9 1997

  191. NIAID and NIH Report 1996 The Relationship Between HIV and AIDS p3

  192. Giraldo R 1997 AIDS and Stressors Fundacion Arte y Cincia, Medellin; Root-Bernstein R 1993 Rethinking AIDS The Free Press, New York; Al Bayati A 1999 Get All the Facts: HIV Does Not Cause AIDS Toxi-Health, Dixon, CA

  193. Root-Bernstein R 1993 Rethinking AIDS The Free Press, New York p220-280; Brody S 1997 Sex at Risk Transaction Publishers, New Brunswick; Plumley P 1995 Condomania: Common Sense or Nonsense? HEAL Bulletin, HEAL New York

  194. Willner R 1994 Deadly Deception p30 Peltec Publishing; The Merck Manual 1992 Immuno-deficiency Diseases p303 Table 19-1 Merck Research Laboratories, Rahway; Fauci A, et al 1998 Principles of Internal Medicine, Edition 14 McGraw Hill, New York

  195. Chandra R 1983 Nutrition, Immunity and Infection Lancet i:688-69. Source: AIDS and Stressors; Merck Manual 1992 Immunodeficiency Diseases p317-318, Immunodeficiency and Malnutrition Merck Research Laboratories, Rahway; Chandra R 1975 Fetal Malnutrition and Postnatal Immunocompetence American Journal of Dis Chil 125:450-455. Source: AIDS and Stressors

  196. Merck Manual 1992 Immunodeficiency Diseases, p304 Table 19-2 Immunosuppressive Agents Merck Research Laboratories, Rahway; Heyer A 1983 Introduction to Nutrition Keats Publishing, New Canaan p2-12; Owen B 1995 You Don't Have to Die Sick Adrenal Exhaustion p43-46 Health Hope Publishing House, Cannon Beach

  197. The American Medical Association Encyclopedia of Medicine 1989 Random House, New York p258

  198. Niwa Y, Yokoyama M 1981 Effect of Glucocorti-costeroid Therapy on the Immune System of Patients with Nonimmunologically Mediated Dermatose J Clin Lab Immunol 6(2):147-155; Parrillo J, Fauci A 1978 Mechanisms of Corticosteroid Action on Lymphocyte Subpopulations of Effector Cells Mediating Cellular Toxicity in Man Clin Exp Immunol 31:116-125; Fauci A. Dale D, Balow J 1976 Glucocorticosteroid Therapy: Mechanisms of Action and Clinical Considerations Annals of Internal Medicine 84:304-15; Leung F, Fam A, Osoba D 1981 Kaposi's Sarcoma Complicating Corticosteroid Therapy for Temporal Arteritis The American Journal of Medicine 71(2):320-322

  199. Merck Manual 1992 Anti-Infective Drugs: Sulfonamides p46-48 Merck Research Laboratories, Rahway; Drugs Facts and Comparisons 1999 Facts and Comparisons Publishing, St. Louis (800) 223-0554

  200. Duesberg P 1996 Inventing The AIDS Virus Regnery Publishing, Washington DC p300

  201. Merck Manual 1992 Anti-Infective Drugs: Sulfonamides p46-48 Merck Research Laboratories, Rahway; Drugs Facts and Comparisons 1999 Facts and Comparisons Publishing, St. Louis (800) 223-0554

  202. Bull Mem Soc Med Hopitaux de Paris, 3rd Ser 1909, 28:958-996; Pharmacology Ther 1992 55: 201-207

  203. Immune System Toxins Rachel's Environment and Health Weekly #536 March 6 1997; Statement on Immune Toxins #544 May 1 1997 Environmental Research Foundation, Annapolis

  204. Hebert C, Brecher M, et al Fewer Blood Transfusions Save Lives New England Journal of Medicine February 1999; United Press International, February 10 1999; Ward, et al 1989 The Natural History of Transfusion Associated Infection With HIV New England Journal of Medicine 321:947-952

  205. Benson H 1997 The Nocebo Effect: History and Physiology Preventive Medicine 26:612-615; Binik Y 1985 Psychosocial Predictors of Sudden Death: A Review and Critique Social Science Medicine 20(7):667-80; Cecchi R 1984 Stress: Prodrome to Immune Deficiency Annals of the New York Academy of Sciences 437:286-289; Cohen S 1988 Voodoo Death, the Stress Response, and AIDS Advanced Biochem Psychopharmacology 44:95-109; Golden K Voodoo in Africa and the United States December 1977 American Journal of Psychiatry 134 (12):1425-1427; Uno H, et al 1989 Hippocampal Damage Associated with Prolonged and Fatal Stress in Primates Journal of Neuroscience 9(5):1705-1711; Milton G Self-Willed Death or the Bone Pointing Syndrome June 23 1973 Lancet 1:1435-1436

  206. Guyton A, Hall J 1996 Textbook of Medical Physiology Sanders, New York p964-965

  207. Cohan J Legally Speaking, Mason v Jacobs 4Front Magazine April 30 1997

  208. Cannon W 1957 Voodoo Death Psychosomatic Medicine 19:182-190 (reprinted from American Anthropologist 44:1942); Campinha-Bacote J 1992 Voodoo Illness Perspectives in Psychiatric Care 28(1):11-17

  209. The American Medical Association Encyclopedia of Medicine 1989 Random House, New York p798

  210. Reuters News Service report, May 14 1998 on Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT), University of Toronto, Canada

  211. Giraldo R 1997 AIDS and Stressors Fundacion Arte y Cincia, Medellin; Root-Bernstein R 1993 Rethinking AIDS The Free Press, New York; Al Bayati A 1999 Get All the Facts: HIV Does Not Cause AIDS Toxi-Health, Dixon, CA

  212. Jagge, et al 1983 Annals of Internal Medicine 99:145-151

  213. Osterloh J, et al 1984 Butyl Nitrite Transformation Invitro Anal Toxicology 8:164-169; Haverkos H, et al 1985 Disease Manifestation Among Homosexual Men with AIDS Sexually Transmitted Diseases 12:203-208; Root-Bernstein R 1990 Do We Know the Cause(s) of AIDS? Pesp Biol Med 33:480-500

  214. Krieger L Kaposi's Sarcoma, AIDS Link Questioned, San Francisco Examiner June 5 1992 pA-1,A-17; US Centers for Disease Control HIV/AIDS Surveillance Report Year-end reports 1993-1998

  215. Marmor, Lancet May 15 1982 (100%); Jaffe, Annals of Internal Medicine 1983 (96%); Harverkos, STD Oct/Nov 1985 (97%); Kaslow, Journal of the American Medical Association 261:23 1989 (96%) Archibald, Epidemiology 3:203 (100%); Duesberg, Genetica, February 1995 (93%)

  216. Yardley J, et al 1980 Immunologic Status in Patients with Giardiasis, Gastroenterology 78: 421-422; Jaffe, et al 1983 Annals of Internal Medicine 99:145-151

  217. Bozzette S, et al 1990 A Controlled Trial of Early Adjunctive Treatment with Corticosteroids for PCP Pneumonia in AIDS New England Journal of Medicine 323 (21):145-7; Traltner A, et al 1993 The Appearance of Kaposi's Sarcoma During Corticosteroid Therapy Cancer 72 (5):1779-1783

  218. Average of two random issues of Edge magazine and Frontiers Gay Biweekly magazine less classified, phone sex, theater and cinema advertisements

  219. Merck Manual 1992 16th edition p55, Merck Research Laboratories; Glaxo-Wellcome information sheet accompanying Zidovudine

  220. Ascher M, et al 1993 Does Drug Use Cause AIDS? Nature 362:103-104; Schecter M, et al 1993 HIV-1 and the Aetiology of AIDS Lancet 341:658-659; Duesberg P 1993 Can Epidemiology Determine Whether Drugs or HIV Cause AIDS? AIDS Forshung 12:627-635

  221. Brody, S 1997 Sex at Risk Transaction Publishers, New Brunswick; 80%: Potterat et al 1987 JAMA 256 p 12; 65%: Renzullo et al 1990 JAIDS 3, p266-271; 83%-90%: Committee on AIDS Research and the Behavioral, Social, and Statistical Sciences 1989; 69%: Chicago Dept of Public Health, Journal of AIDS 1997; 99.4%: NYC Dept of Health, American Journal of Epidemiology 137:2

  222. Duesberg P, Rasnick D 1998 The AIDS Dilemma: Drug Diseases Based on a Passenger Virus, Genetica 104: p109 Table 7

  223. Achard G, Bernard H, et al 1909 Action de la Morphine sur les Proprietes Leucocytaires; Leucodiagnostic du Morphinisme Bulletin et Memoires de la Societe Medicale des Hopitaux de Paris 28, 3rd Series:958-966; Terry C, Pellens M 1928 The Opium Problem Bureau of Social Hygiene of New York; Briggs J, McKerron C, et al 1967 Severe Systemic Infection Complicating "Mainline" Heroin Addiction Lancet ii:1227-1231; Sapira J 1968 The Narcotic Addict as a Medical Patient Am J Med 45:555-558; Harris P, Garret R 1972 Susceptibility of Addicts to Infection and Neoplasia New Engl J Med 287:310; Geller S, Stimmel B 1973 Diagnostic Confusion from Lymphatic Lesions in Heroin Addicts Ann Intern Med 78:703-705; Pillari G, Narus J 1973 Physical Effects of Heroin Addiction Am J Nursing 73:2105-2109; Brown S, Stimmel B, et al 1974 Immunologic Dysfunction in Heroin Addicts Arch Intern Med 134:1001-1006; Louria D 1974 Infectious Complications of Nonalcoholic Drug Abuse Annu Rev Med 25:219-231; McDonough R, Madden J, et al 1980 Alteration of T and Null Lymphocyte Frequencies in the Peripheral Blood of Human Opiate Addicts: In Vivo Evidence of Opiate Receptor Sites on T Lymphocytes J Immunol 125:2539-2543; Gottlieb M, Schanker H, et al 1981 Pneumocystis PneumoniaLos Angeles Morbidity and Mortality Weekly Reports 30:250-252; Marmor M, Friedman-Kien A, et al 1982 Risk Factors for Kaposi's Sarcoma in Homosexual Men Lancet i:1083-1087; Jaffe H, Choi K, et al 1983 National Case-Control Study of Kaposi's Sarcoma and Pneumocystis Carinii Pneumonia in Homosexual Men: Part 1, Epidemiological Results Ann Intern Med 99:145-151; Tubaro E, Borelli G, et al 1983 Effect of Morphine on Resistance to Infection J Infect Dis 148:656-666; Layon J, Idris A, et al 1984 Altered T Lymphocyte Subsets in Hospitalized Intravenous Drug Abusers Arch Intern Med 144:1376-1380; Newell G, Mansell P, et al 1985a Volatile Nitrites: Use and Adverse Effects Related to the Current Epidemic of Acquired Immune Deficiency Syndrome Am J Med 78:811-816; Newell G, Mansell P, et al 1985b Risk Factor Analysis Among Men Referred for Possible Acquired Immune Deficiency Syndrome Preventive Med 14:81-91; Culver K, Ammann A, et al 1987 Lymphocyte Abnormalities in Infants Born to Drug-Abusing Mothers J Pediatr 111:230-235; Donahoe R, Bueso-Ramos C, et al 1987 Mechanistic Implications of the Findings that Opiates and Other Drugs of Abuse Moderate T-cell Surface Receptors and Antigenic Markers Ann N.Y. Acad Sci 496:711-721; Bureau of Justice Statistics 1988 Special ReportDrug Law Violators, 1980-1986 US Department of Justice, Washington DC; Haverkos H, Dougherty J (eds) 1988b Health Hazards of Nitrite Inhalants US Department of Health and Human Services, Washington DC; Selwyn P, Feingold A, et al 1988 Increased Risk of Bacterial Pneumonia in HIV-Infected Intravenous Drug Users without AIDS AIDS 2:267-272; Novick O, Ochshorn M, et al 1989 Natural Killer Cell Activity and Lymphocyte Subsets in Parenteral Heroin Abusers and Long-Term Methadone Maintenance Patients The Journal of Pharmacology and Experimental Therapeutics 250:606-610; Mientjes G, Miedema F, et al 1991 Frequent Injecting Impairs Lymphocyte Reactivity in HIV-Positive and HIV-Negative Drug Users AIDS 5:35-41; Pillai R, Nair B, et al 1991 AIDS, Drugs of Abuse and the Immune System: A Complex Immunotoxicological Network Arch Toxicol 65:609-617; Larrat P, Zierler S 1993 Entangled Epidemics: Cocaine Use and HIV Disease J Psychoactive Drugs 25:207-221; Mientjes G, van Ameijden E, et al 1993 Clinical Symptoms Associated with Seroconversion for HIV-1 among Misusers of Intravenous Drugs: Comparison with Homosexual Seroconverters and Infected and Non-Infected Intravenous Drug Misusers Br. Med. J. 306:371-373; Sadownick D 1994 Kneeling at the Crystal Cathedral Genre December/January 1994 p40-45, 86-90; Ratajczak H, Thomas P, et al 1995 Local Versus Systemic Immunotoxicity of Isobutyl Nitrite Following Subchronic Inhalation Exposure of Female B6C3F1 Mice Fundamental and Applied Technology 27:177-184; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  224. Jaffe H, Choi K, et al 1983 National Case-Control Study of Kaposi's Sarcoma and Pneumocystis Carinii Pneumonia in Homosexual Men: Part 1, Epidemiological Results Ann Intern Med 99:145-151; Newell G, Adamas S, et al 1984 Toxicity, Immunosuppressive Effects and Carcinogenic Potential of Volatile Nitrites: Possible Relationship to Kaposi's Sarcoma Pharmacotherapy 4:284-291; Haverkos H, Pinsky P, et al 1985 Disease Manifestation Among Homosexual Men with Acquired Immunodeficiency Syndrome: A Possible Role of Nitrites in Kaposi's Sarcoma J Sex Trans Dis 12:203-208; Haverkos H, Kaposi's Sarcoma and Nitrite Inhalants In: Psychological, Neuropsychiatric and Substance Abuse Aspects of AIDS by Bridge T, Heather H, Johnson M (eds) Raven Press, New York p165-172; Haverkos H, Dougherty J 1988a Health Hazards of Nitrite Inhalants Am J Med 84:479-482; Archer C, Spittle M, et al 1989 Kaposi's Sarcoma in a Homosexual10 Years On Clin Exper Dermatol 14:233-236; Friedman-Kien A, Saltzman B, et al 1990 Kaposi's Sarcoma in HIV-Negative Homosexual Men Lancet 335:168-169; Marquart K, Engst R, et al 1991 An 8-Year History of Kaposi's Sarcoma in an HIV-Negative Bisexual Man AIDS 5:346-348; Safai B, Peralta H, et al 1991 Kaposi's Sarcoma among HIV-Negative High Risk Populations VII International Conference on AIDS, Florence, Italy

  225. Pillari G, Narus J 1973 Physical Effects of Heroin Addiction Am J Nursing 73:2105-2109; Stoneburner R, Des Jarlais D, et al 1988 A Larger Spectrum of Severe HIV-1-Related Disease in Intravenous Drug Users in New York City Science 242:916-919; Rogers M, Ou C, et al 1989 Use of the Polymerase Chain Reaction for Early Detection of the Proviral Sequences of Human Immunodeficiency Virus in Infants Born to Seropositive Mothers N Engl J Med 320:1649-1654

  226. Gottlieb M, Schanker H, et al 1981 Pneumocystis PneumoniaLos Angeles Morbidity and Mortality Weekly Reports 30:250-252; Jaffe H, Choi K, et al 1983 National Case-Control Study of Kaposi's Sarcoma and Pneumocystis Carinii Pneumonia in Homosexual Men: Part 1, Epidemiological Results Ann Intern Med 99:145-151; Mathur-Wagh U, Enlow R, et al 1984 Longitudinal Study of Persistent Generalized Lymphadenopathy in Homosexual Men: Relation to Acquired Immunodeficiency Syndrome Lancet i:1033-1038; Mathur-Wagh U, Mildvan D, et al 1985 Follow-Up of 41/2 Years on Homosexual Men with Generalized Lymphadenopathy N Engl J Med 313:1542-1543; Selwyn P, Feingold A, et al 1988 Increased Risk of Bacterial Pneumonia in HIV-Infected Intravenous Drug Users without AIDS AIDS 2:267-

  227. Geller S, Stimmel B 1973 Diagnostic Confusion from Lymphatic Lesions in Heroin Addicts Ann Intern Med 78:703-705; Pillari G, Narus J 1973 Physical Effects of Heroin Addiction Am J Nursing 73:2105-2109; Espinoza P, Bouchard I, et al 1987 High Prevalence of Infection by Hepatitis B Virus and HIV in Incarcerated French Drug Addicts Gastroenterologie Clinique et Biologique 11:288-292; Des Jarlais D, Friedman S, et al 1988 Risk Reduction of the Acquired Immune Deficiency Syndrome among Intravenous Drug Users In: AIDS and IV Drug Abusers: Current Perspectives by Galea R, Lewis B, Baker L (eds) National Health Publishing, Owings Mills, MD p97-109; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  228. Firooznia H, Seliger G, et al 1973 Disseminated Extrapulmonary Tuberculosis in Association with Heroin Addiction Radiology 109:291-296; Courtwright D 1982 Dark Paradise: Opiate Addiction in America Before 1940 Harvard University Press, Cambridge, MA; Layon J, Idris A, et al 1984 Altered T Lymphocyte Subsets in Hospitalized Intravenous Drug Abusers Arch Intern Med 144:1376-1380; Stoneburner R, Des Jarlais D, et al 1988 A Larger Spectrum of Severe HIV-1-Related Disease in Intravenous Drug Users in New York City Science 242:916-919; Braun M, Truman B, et al 1989 Increasing Incidence of Tuberculosis in a Prison Inmate Population, Associated with HIV Infection J Am Med Assoc 261:393-397; Brudney K, Dobkin J 1991 Resurgent Tuberculosis in New York City Am Rev Respir Dis 144:744-749; Hayes T, Altman R, et al 1994 HIV-Related Deaths from Selected Infectious Diseases among Persons without AIDS in New Jersey Journal of Acquired Immune Deficiency Syndromes 7:1074-1078

  229. Pillari G, Narus J 1973 Physical Effects of Heroin Addiction Am J Nursing 73:2105-2109; Des Jarlais D, Friedman S, et al1988 Risk Reduction of the Acquired Immune Deficiency Syndrome among Intravenous Drug Users In: AIDS and IV Drug Abusers: Current Perspectives by Galea R, Lewis B, Baker L (eds) National Health Publishing, Owings Mills, MD p97-109; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165; Bergling T 1997 All Methed Up: Doing Crystal Meth Will Lift You Up Until You Break Genre 53:October p45-47,88; McEvoy A, Kitchen N, et al 1998 Intracerebral Haemorrhage Caused by Drug Abuse Lancet 351:1029

  230. Stoneburner R, Des Jarlais D, et al 1988 A Larger Spectrum of Severe HIV-1-Related Disease in Intravenous Drug Users in New York City Science 242:916-919; Koch T July 30 1990 Uninfected Children of HIV-Infected Mothers May Still Suffer Nervous Problems CDC AIDS Weekly p9; Aylward E, Butz A, et al 1992 Cognitive and Motor Development in Infants at Risk for Human Immunodeficiency Virus Am J Dis Child 146:218-222; Larrat P, Zierler S 1993 Entangled Epidemics: Cocaine Use and HIV Disease J Psychoactive Drugs 25:207-221; Hayes T, Altman R, et al 1994 HIV-Related Deaths from Selected Infectious Diseases among Persons without AIDS in New Jersey Journal of Acquired Immune Deficiency Syndromes 7:1074-1078; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165; McEvoy A, Kitchen N, et al 1998 Intracerebral Haemorrhage Caused by Drug Abuse Lancet 351:1029

  231. Des Jarlais D, Friedman S, et al 1988 Risk Reduction of the Acquired Immune Deficiency Syndrome among Intravenous Drug Users In: AIDS and IV Drug Abusers: Current Perspectives by Galea R, Lewis B, Baker L (eds) National Health Publishing, Owings Mills, MD p97-109; Muñoz A, Vlahov D, et al 1992 Prognostic Indicators for Development of AIDS among Intravenous Drug Users J Acquir Immune Defic Syndr 5:694-700; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  232. Des Jarlais D, Friedman S, et al 1988 Risk Reduction of the Acquired Immune Deficiency Syndrome among Intravenous Drug Users In: AIDS and IV Drug Abusers: Current Perspectives by Galea R, Lewis B, Baker L (eds) National Health Publishing, Owings Mills, MD p97-109; Ettinger N, Albin R 1989 A Review of the Respiratory Effects of Smoking Cocaine Am J Med 87:664-668; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  233. Savona S, Nardi M, et al 1985 Thrombocytopenic Purpura in Narcotics Addicts Ann Intern Med 102:737-741

  234. Fricker H, Segal S 1978 Narcotic Addiction, Pregnancy, and the Newborn Am J Dis Child 132:360-366; Lifschitz M, Wilson G, et al 1983 Fetal and Postnatal growth of Children Born to Narcotic-Dependent Women J Pediatr 102:686-691; Alroomi L, Davidson J, et al 1988 Maternal Narcotic Abuse and the Newborn Arch Dis Child 63:81-83; Rogers M, Ou C, et al 1989 Use of the Polymerase Chain Reaction for Early Detection of the Proviral Sequences of Human Immunodeficiency Virus in Infants Born to Seropositive Mothers N Engl J Med 320:1649-1654; Toufexis A May 13 1991 Innocent Victims Time p56-60; Finnegan L, Mellot J, et al 1992 Perinatal Exposure to Cocaine: Human Studies In: Cocaine: Pharmacology, Physiology and Clinical Strategies by Lakoski J, Galloway M, White F (eds) CRC Press, Boca Raton, FL p391-409; Larrat P, Zierler S 1993 Entangled Epidemics: Cocaine Use and HIV Disease J Psychoactive Drugs 25:207-221

  235. Des Jarlais D, Friedman S, et al 1988 Risk Reduction of the Acquired Immune Deficiency Syndrome among Intravenous Drug Users In: AIDS and IV Drug Abusers: Current Perspectives by Galea R, Lewis B, Baker L (eds) National Health Publishing, Owings Mills, MD p97-109; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  236. Larrat P, Zierler S 1993 Entangled Epidemics: Cocaine Use and HIV Disease J Psychoactive Drugs 25:207-221; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  237. Wilson J, Kalasinsky K, et al 1996 Striatal Dopamine Nerve Terminal Markers in Human, Chronic Methamphetamine Users Nature Medicine 2:699-703

  238. Pillari G, Narus J 1973 Physical Effects of Heroin Addiction Am J Nursing 73:2105-2109

  239. Pillari G, Narus J 1973 Physical Effects of Heroin Addiction Am J Nursing 73:2105-2109; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  240. Dismukes W, Karchmer A, et al 1968 Viral Hepatitis Associated with Illicit Parenteral Use of Drugs J Am Med Assoc 206:1048-1052; Pillari G, Narus J 1973 Physical Effects of Heroin Addiction Am J Nursing 73:2105-2109; Layon J, Idris A, et al 1984 Altered T Lymphocyte Subsets in Hospitalized Intravenous Drug Abusers Arch Intern Med 144:1376-1380

  241. Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  242. Layon J, Idris A, et al 1984 Altered T Lymphocyte Subsets in Hospitalized Intravenous Drug Abusers Arch Intern Med 144:1376-1380; Stoneburner R, Des Jarlais D, et al 1988 A Larger Spectrum of Severe HIV-1-Related Disease in Intravenous Drug Users in New York City Science 242:916-919; Mientjes G, van Ameijden E, et al 1993 Clinical Symptoms Associated with Seroconversion for HIV-1 among Misusers of Intravenous Drugs: Comparison with Homosexual Seroconverters and Infected and Non-Infected Intravenous Drug Misusers Br. Med. J. 306:371-373; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165

  243. Indiana Hemophilia Foundation. Source: Duesberg P 1996 Inventing the AIDS Virus Regnery Publishing, Washington DC p287-288

  244.  

  245. Blood Transfusions: Fewer Blood Transfusions Save Lives United Press International February 10 1999; Hebert P, et al New England Journal of Medicine February 11 1999

  246. Brody, S 1997 Sex at Risk Transaction Publishers, New Brunswick; 80%: Potterat et al 1987 JAMA 256 p 12; 65%: Renzullo, et al 1990 JAIDS 3, p266-271; 83%-90%: Committee on AIDS Research and the Behavioral, Social, and Statistical Sciences 1989; 69%: Chicago Dept of Public Health, Journal of AIDS 1997; 99.4%: NYC Dept of Health, American Journal of Epidemiology 137:2

  247. Fumento M Washington Times June 8 1999

  248. US Centers for Disease Control 1999 HIV/AIDS Surveillance Report Year-end 1998 p14 Table 5

  249. Altman L Outside of US and Europe HIV Transmission is Through Heterosexual Contact New York Times November 2 1993

  250. Biggar R, et al 1985 ELISA HTLV Retrovirus Antibody Reactivity Associated With Malaria Lancet ii 520-543; Charmot G, Simon F 1990 HIV Infection and Malaria Revue Du Practien 40:2124; Bush, et al Journal of AIDS 5:872 1992; Kashala O, et al 1994 Infection with HIV-1 and Human T Cell Lymhotropic Viruses Among Leprosy Patients and Contacts Journal of Infectious Diseases 169:292-304

  251. Piatak M, et al 1993 Science 259:1749-53 

  252. World Health Organization annual conversions rates. Source: Willner R Deadly Deception Peltec Publishing p39-41

  253. Benthen B, et al Insights from the Tricontinental Seroconverter Study AIDS June 18 1998 12:1039-1045; New England Journal of Medicine 1995 332:209; Journal of Infectious Diseases 1996 173:60

  254. Buchbinder S, et al 1994 Long Term HIV 1 Infection Without Immunologic Progression AIDS 8:1123; Pantaleo G, et al 1995 Studies in Subjects with Long-Term Non-Progressive HIV Infection New England Journal of Medicine 332(4):209-216; Muñoz A, et al 1995 Long-Term Survivors of HIV-1 Infection Journal of AIDS and Human Retrovirology April 15 8(5):496-505

  255. Journal InterAM Medical Health Association 1992 1:1-8

  256. Callen M Surviving AIDS Harper-Collins Publishing; Root-Bernstein R Rethinking AIDS The Free Press, New York p361-363; Time Magazine March 22 1993; Gregory S, Leonardo B 1992 They Conquered AIDS: True Life Adventures; MacIntyre R, Mortal Men: Living with Asymptomatic HIV University Press, Rutgers; Chaitow L, Strohecker J 1997 You Don't Have to Die: Unraveling the AIDS Myth Future Medicine Publishing

  257. Genetica 1996 AIDS: Virus or Drug Induced? p3-22; Ostrom N The T4 Myth New York Native May 2 1994

  258. Bird A 1996 Non-HIV AIDS Journal of Antimicrobial Chemotherapy 37(B):171-183; Haynes S California State Department of Health Services AIDS Study. Source: Farber C SPIN magazine May 1994

  259. Mosley J Transfusion Safety Study Group Report presented at 1993 International AIDS conference. Source: Farber C SPIN magazine May 1994

  260. Fleming T, De Mets D Surrogate End Points in Clinical Trials: Are We Being Misled? Annals of Internal Medicine October 1 1996 125:605-613

  261. Carney W, Rubin R, et al Analysis of T Lymphocyte Subsets in CMV Mononucleosis June 1981 Journal of Immunology; Feeney C, Bryzman S, et al October 1995 T-Lymphocyte Subsets in Acute Illness Critical Care Medicine 23 (10):1680-1685

  262. US Centers for Disease Control, 1998 Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents

  263. Source for entire section: The American Association of Oriental Medicine Understanding Oriental Medicine, Acupuncture and Herbology Catasauqua, PA; Cassileth B PhD The Alternative Medicine Handbook WW Norton & Co, New York; The Complete Guide to Alternative And Conventional Treatments Time Life Books, Alexandria; Mortimore D The Complete Illustrated Guide to Nutritional Healing, Element Press, Boston; New Choices in Natural Healing, Rodale Press Inc., Emmaus; Tips J PhD Your Liver...Your Lifeline: Detoxification and Rejuvenation for the Whole Body Apple-A-Day Press, Austin; Jensen B PhD DC Tissue Cleansing Through Bowel Management Bernard Jensen International, Escondido

  264. POZ Magazine July 1992

  265. Schwartz D, et al 1997 Extensive Evaluation of a Seronegative Participant in an HIV-1 Vaccine Trial as a Result of False-Positive PCR, Lancet Vol 350 No 9073 p256

  266. Wall Street Journal May 1 1996

  267. American Heritage Dictionary Second College Edition Houghton Mittlin Company, Boston p492

  268. Documentary film HIV=AIDS: Fact or Fraud Starvision Productions Denver CO 1997; CNN Website Massive Trial of AIDS Vaccine to Begin in Thailand February 10 1999 8:27 pm EST

  269. Altman L Inherited Factor May Play Role in Risk of AIDS New York Times May 10 1987

  270. Stoneburner R, Des Jarlais D, et al 1988 A Larger Spectrum of Severe HIV-1-Related Disease in Intravenous Drug Users in New York City Science 242:916-919; Ettinger N, Albin R 1989 A Review of the Respiratory Effects of Smoking Cocaine Am J Med 87:664-668; Mientjes G, van Ameijden E, et al 1993 Clinical Symptoms Associated with Seroconversion for HIV-1 among Misusers of Intravenous Drugs: Comparison with Homosexual Seroconverters and Infected and Non-Infected Intravenous Drug Misusers Br. Med. J. 306:371-373; Hayes T, Altman R, et al 1994 HIV-Related Deaths from Selected Infectious Diseases among Persons without AIDS in New Jersey Journal of Acquired Immune Deficiency Syndromes 7:1074-1078; Brettle R 1996 Clinical Features of Drug Use and Drug Use Related to HIV Int J STD & AIDS 7:151-165 

Â